The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
about
The crystal structure of Lactococcus lactis dihydroorotate dehydrogenase A complexed with the enzyme reaction product throws light on its enzymatic functionWhen a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?Leflunomide: mode of action in the treatment of rheumatoid arthritisThe active metabolite of leflunomide, A77 1726, interferes with dendritic cell functionLactococcus lactis dihydroorotate dehydrogenase A mutants reveal important facets of the enzymatic functionPharmacogenetics of treatment response in psoriatic arthritisDihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosisThe combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replicationPharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method.The Open Form Inducer Approach for Structure-Based Drug Design.Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domainHigh-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.Treatment advances in rheumatoid arthritisAnalysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Combination therapy for autoimmune diseases: the rheumatoid arthritis model.The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.Anti-inflammatory and Anti-arthritic Effects of a Novel Leflunomide Analogue, UTL-5b (GBL-5b).Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification.Persistent immune activation in chronic HIV infection: do any interventions work?Oral disease-modifying therapies for multiple sclerosis.Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.Leflunomide for the treatment of rheumatoid arthritis.Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue culturesTyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virusInhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.Leflunomide in renal transplantation.Pharmacogenetics: implications for therapy in rheumatic diseases.Teriflunomide: a review of its use in relapsing multiple sclerosis.Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes.Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients.The mammalian homologue of Prp16p is overexpressed in a cell line tolerant to Leflunomide, a new immunoregulatory drug effective against rheumatoid arthritis.Structures of Medicago truncatula L-Histidinol Dehydrogenase Show Rearrangements Required for NAD+ Binding and the Cofactor Positioned to Accept a Hydride.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
P2860
Q24673034-6DE9282A-F6AA-4F14-914A-B7CEA879DF2CQ24673434-83608040-6A36-4F42-BF7D-56B5ECE2AFBEQ24675005-901EA1A1-265C-47CB-AE80-D96A2A912C05Q24816880-CEA6D8A8-C84B-4AA7-8D02-90B85921A4CBQ27641154-4923F52E-24BD-40AB-855D-3CE7F2C6156FQ28081252-D3ACDBCC-3420-4450-BE3F-C51F60DC4AD4Q28279963-C46E3B9D-8BEA-40BD-9A2A-8E6179D995F0Q28545087-68FA1D93-B75C-411F-A812-5ABB59B3585CQ28547166-C49240E5-DCC5-40DC-84D3-8E5A9BB4843AQ28554455-13BBCDB9-523F-4EA7-9C1D-EC5451978505Q28581357-7BB738B2-6FD2-4F8C-9600-991BAE04F1A9Q31156888-BBB6388A-FAB3-40A6-B9A1-562F13DC0A18Q33614540-39CB2B78-83AA-4957-AA38-68FE08816F35Q33667903-22301333-82E2-4B0E-A7B9-307EDA3282A8Q33844680-4A451DB5-8B79-48E9-8BBB-9FC2B221FD7AQ33903812-4DEA7A23-8030-4F29-B074-56D9ED22D984Q33918869-7047E091-C732-40B7-8CFB-4E4C406CE396Q34066654-A4917E8A-0BCC-4D1F-98B4-B62BF5804C88Q34309751-0A16D5D5-E742-49C5-A96E-4D55FA8457F4Q34345424-FC5A9876-91CB-4A76-A7F9-77B2CC977CD7Q34497665-AB337FF9-B2FC-498F-A052-3EAB95DE2B04Q34520015-CA876236-EB4C-4322-A809-1C48FB4BD4D3Q34851102-C7F21F49-1240-48BC-9D75-6D8415DEFC15Q34996562-91EE219A-D762-4DD5-8B08-E2E8E42A971DQ35047952-483F4B11-B493-4E4F-9288-3145E9ACDA67Q35143977-98DEFD14-EB9C-426A-AF0F-CDCAF8B8EF64Q35552561-712C1642-6CF5-4450-8B8F-FE8700CA38F6Q35552648-C803BBDF-AEDA-4F9A-AEE0-008AECAD172CQ36181201-2F510D26-C66E-44A2-BDC2-7C1518271AA9Q36662024-C90313DC-D2C3-46A7-9F6A-53F3645D6D0EQ37144432-8B55418D-676F-4DED-9043-7E3C8329B434Q37580399-DAC224B8-7E8B-4A68-B797-BBBDF0B9BA60Q37877256-8C8E0B72-6139-4029-A23D-55E49E326E6AQ37913989-D2D06CC8-ADA5-46E7-85E7-5B29E5C17FDBQ38160410-B02FB19C-C509-4EF8-BC19-FB8878F16B3FQ39455814-0D6F4600-EDDF-448E-A4F6-CF6D2AD0F5B1Q40354910-56B052BA-2D94-48BC-96AB-8FE7B323AC80Q41017180-AD5906D4-E269-404F-8032-A54C22746026Q41619763-804C0ABF-0F4E-430C-9347-82F880D9D9DEQ41877062-F9A6482C-12A6-4FD8-8741-C0DF1C6F0AF8
P2860
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@ast
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@en
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@nl
type
label
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@ast
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@en
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@nl
prefLabel
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@ast
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@en
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@nl
P2093
P356
P1433
P1476
The immunosuppressive metaboli ...... dihydroorotate dehydrogenase.
@en
P2093
P304
P356
10.1021/BI952168G
P407
P577
1996-01-01T00:00:00Z